Skip Navigation

European Heart Journal 1995 16(Supplement D):28-32; doi:10.1093/eurheartj/16.suppl_D.28
Copyright © 1995 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Fox, K. A. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fox, K. A. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1995 The European Society of Cardiology

r-Hirudin in unstable angina pectoris Rationale and preliminary data from the APT pilot study

K. A. A. Fox*

Cardiovascular Research Unit, Hugh Robson Building George Square, Edinburgh EH8 9XF, U.K.

Correspondence: Professor K. A. A. Fox. Cardiovascular Research Unit. The University of Edinburgh. Hugh Robson Building. George Square, Edinburgh EH8 9XF

Therapeutic strategies for patients with unstable angina have been hampered by the difficulty in defining a homogenous cohort of patients, and identifying their risk for subsequent cardiovasular events. Despite the similarities in pathophysiological mechanisms between unstable angina and acute myocardial infarction, an analysis of recent trials of thrombolytic therapy in unstuble angina has failed to reveal evidence of improved clinical outcome. However, both aspirin and heparin have shown evidence of benefit and in order to test more specific andpotent thrombin inhibitors (for example hirudin) it is necessary to identify a cohort of patients with a high risk of subsequent cardiac events.

This small scale pilot study set out to identify patients with unstable angina or non-Q wave infarction with a high risk of subsequent cardiac events and to undertake a feasibility study of two dose regimens of recombinant hirudin (HP W023). The impact on haemostatic parameters and the need for dose adjustment in order to achieve the target therapeutic range of activated partial thromboplastin time (aPTT) was also assessed. Firstly, the study revealed that it was possible to identify a high risk patient population (6143, 14% had sustained infarction; 10143, 23% required emergency or urgent revascularization and 11143, 26% elective revascularization). Secondly, it was possible to achieve stable antithrombin regimens with the two selected doses of hirudin (at least 78% of patients were within the target range at any of the time points). Haemostatic parameters were compared, but larger scale studies are required to establish safety, with a reliable estimate of the impact of hirudin on clinical events.

Key Words: Unstable angina • non-Q wave infarction • heparin • hirudin

* On behalf of the Study Investigators—see Appendix


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.